Neuromuscul Disord. 2011 Jan;21(1):4-12. Epub 2010 Nov 4. Stem cells to treat muscular dystrophies – where are we? Meng J, Muntoni F, Morgan JE. Source The Dubowitz Neuromuscular Centre, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom. Abstract The muscular dystrophies are inherited disorders characterised by progressive muscle wasting and […]
Read More…2011 Jan;21(1):4-12. Epub 2010 Nov 4. Stem cells to treat muscular dystrophies – where are we? Meng J, Muntoni F, Morgan JE. The Dubowitz Neuromuscular Centre, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom. Abstract The muscular dystrophies are inherited disorders characterised by progressive muscle wasting and weakness. Stem cell […]
Read More…2010;16(8):988-1001 Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy. Wilton SD, Fletcher S Abstract In little more than a decade, induced exon skipping as a therapy to treat Duchenne muscular dystrophy (DMD) has progressed from a concept tested in vitro, to pre-clinical evaluation in mouse and dog models, and recent completion of […]
Read More…2010 Sep; 42(7) : 2731-9 Microdystrophin Delivery in Dystrophin-Deficient (mdx) Mice by Genetically-Corrected Syngeneic MSCs Transplantation. Xiong F, Xu Y, Zheng H, Lu X, Feng S, Shang Y, Li Y, Zhang Y, Jin S, Zhang C Abstract Cell transplantation and gene therapy are two promising therapeutical approaches for the treatment on Duchenne Muscular Dystrophy (DMD). […]
Read More…2010 Aug 1;24(4):237-47 Stem cell therapies to treat muscular dystrophy: progress to date. Meregalli M, Farini A, Parolini D, Maciotta S, Torrente Y Abstract Muscular dystrophies are heritable, heterogeneous neuromuscular disorders and include Duchenne and Becker muscular dystrophies (DMD and BMD, respectively). DMD patients exhibit progressive muscle weakness and atrophy followed by exhaustion of muscular […]
Read More…2010 Aug 24; Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice. Verma M, Asakura Y, Hirai H, Watanabe S, Tastad C, Fong GH, Ema M, Call JA, Lowe DA, Asakura A Abstract Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disease caused by mutations in the gene coding for […]
Read More…2010 Aug 1;24(4):237-47 Stem cell therapies to treat muscular dystrophy: progress to date. Meregalli M, Farini A, Parolini D, Maciotta S, Torrente Y Abstract Muscular dystrophies are heritable, heterogeneous neuromuscular disorders and include Duchenne and Becker muscular dystrophies (DMD and BMD, respectively). DMD patients exhibit progressive muscle weakness and atrophy followed by exhaustion of muscular […]
Read More…2010 Aug;69(8):771-6 Targeting fibrosis in Duchenne muscular dystrophy. Zhou L, Lu H Abstract Duchenne muscular dystrophy (DMD) is the most common genetic muscle disease affecting 1 in 3,500 live male births. It is an X-linked recessive disease caused by a defective dystrophin gene. The disease is characterized by progressive limb weakness, respiratory and cardiac failure, […]
Read More…2010 Jul;160(6):1550-60 Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Sciorati C, Buono R, Azzoni E, Casati S, Ciuffreda P, D’Angelo G, Cattaneo D, Brunelli S, Clementi E Abstract Current therapies for muscular dystrophy are based on corticosteroids. Significant side effects associated with these […]
Read More…2010;52(5):399-406 Structure of neuromuscular junctions and differentiation of striated muscle fibers of mdx mice after bone marrow stem cells therapy. Sokolova AV, Zenin VV, MikhaÄlov VM Mdx mice are a model of Duchenne muscular dystrophy caused by deficiency of dystrophin. Muscles of mdx mice are characterized by high levels of striated muscle fibers death and, […]
Read More…